Emily heralded as breakthrough in DUB management

Posted on 22 Feb 2013 | Posted in Innovations

" To adequately bridge the gender gap in medication management, we need to emphasize more research on women from the very beginning of the drug discovery process..."

Apart from providing economic opportunities, political liberties and social powers, adequate healthcare and nutrition are also vital in bringing women forward in the society. It has been realized by social scientists, health organizations and other providers of health care that woman empowerment can be better realized through improving their health standards by providing sufficient medication and appropriate healthcare facilities.

Being a globally acclaimed healthcare company HLL Lifecare Ltd has been conducting intense research and studies to prevent and eradicate health issues of women to stimulate women empowerment and health enhancement of the families in the country.

HLL’s R&D division introduced a new Intra Uterine hormonal System (IUS), Emily, for cost effective management of Dysfunctional Uterine bleeding (DUB). Emily has the potential to specifically treat a range of pre-existing gynecological conditions such as heavy menstrual bleeding due to a wide range of underlying causes, endometrial hyperplasia, uterine fibroids, adenomyosis, and endometriosis.

Around 30 percent of women in the world suffer from DUB and almost 20 percent of them have been referred to undergo hysterectomy, making it one of the most common and major gynecological operation.  Emily releases Levonorgestrel (LNG) hormone in a controlled way for a period of five years to offer therapeutic action for contraception and to prevent heavy menstrual bleeding. The device is removable when the user desires to conceive baby.

“We are also glad to find a remedy for the most major health issue of women. Most of the women opt for surgery to get rid of the pain. Making public healthcare affordable has always been our motto. Emily comes as the latest offering from our stable for reliable and cost-effective healthcare solutions,” said C&MD Dr. M. Ayyappan.

The much-awaited device marks the culmination of longstanding collaboration between HLL and Sree Chitra Tirunal Institute of Medical Sciences and Technology, Thiruvananthapuram, in the state of Kerala which has been instrumental in developing the technology behind the product. Emily is the only generic version currently available in the world.

Emily, the  first of its kind indigenous product in India,  will be available in the market in Pan India scale from March 2013 onwards for a ground breaking low price of Rs 2424 when compared to the other imported IUDs in the market costing an average of 9000rupees for a piece. The product will also be exposed to top gynecologists in the country and in premier teaching institutes like AIIMS, New Delhi.

Leave a comment